Document Detail

311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients.
MedLine Citation:
PMID:  21729166     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Treatment with the tumor necrosis factor-alpha antibody adalimumab for 12-16 weeks produces a satisfactory response [i.e., 75% reduction in psoriasis area and severity index (PASI)] in a majority (70-80%) of patients with psoriasis. We asked whether 311 nm ultraviolet B (UVB) can improve therapeutic response of psoriatic lesions to adalimumab.
METHODS: Four patients (age range, 49-67 years) with moderate to severe plaque-type psoriasis were treated with standard dosage of adalimumab. During adalimumab therapy, a randomly selected body half (left or right, excluding the head) was irradiated with 311 nm UVB three times weekly for 6 weeks. Treatment response was monitored weekly in terms of half-body PASI.
RESULTS: 311 nm UVB significantly accelerated the therapeutic response during adalimumab treatment. At the start of 311 nm UVB therapy, the mean PASI was 14.8. After 6 weeks of 311 nm UVB therapy, the mean PASI was 2.0 on UV-irradiated body halves and 6.9 on non-irradiated body halves (difference, 4.9; 95% confidence interval, 0.4-9.4; P=0.041; 2-tailed paired t-test). This corresponded to an overall mean PASI reduction from baseline (i.e., adalimumab start) of 86% on UV-irradiated body halves vs. 53% on non-irradiated body halves.
CONCLUSION: 311 nm UVB may accelerate and improve the clearance of psoriatic lesions in adalimumab-treated patients.
Peter Wolf; Angelika Hofer; Wolfgang Weger; Timea Posch-Fabian; Alexandra Gruber-Wackernagel; Franz J Legat
Related Documents :
19574206 - Quality of life two years after radical prostatectomy, prostate brachytherapy or extern...
10431406 - Treatment of bph with transurethral electrovaporization of the prostate (tuvp) using va...
16985896 - Pde-5 inhibitor therapy for erectile dysfunction secondary to nerve-sparing radical ret...
84866 - Transsphenoidal hypophysectomy for disseminated carcinoma of the prostate gland. result...
22350036 - A randomized clinical trial on the clinical and microbiological efficacy of a xanthan g...
12823436 - Topical ascorbic acid on photoaged skin. clinical, topographical and ultrastructural ev...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Photodermatology, photoimmunology & photomedicine     Volume:  27     ISSN:  1600-0781     ISO Abbreviation:  Photodermatol Photoimmunol Photomed     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-06     Completed Date:  2011-11-01     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9013641     Medline TA:  Photodermatol Photoimmunol Photomed     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  186-9     Citation Subset:  IM    
Copyright Information:
© 2011 John Wiley & Sons A/S.
Research Unit for Photodermatology, Department of Dermatology, Medical University of Graz, Graz, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Combined Modality Therapy
Middle Aged
Psoriasis / therapy*
Remission Induction
Ultraviolet Rays*
Ultraviolet Therapy*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The impact of different fluence rates on pain and clinical outcome in patients with actinic keratose...
Next Document:  Differences in sun exposure habits between self-reported skin type and ultraviolet sensitivity measu...